M
Mo Yin
Researcher at National University of Singapore
Publications - 11
Citations - 223
Mo Yin is an academic researcher from National University of Singapore. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 4, co-authored 6 publications receiving 122 citations.
Papers
More filters
Journal ArticleDOI
Association between minimum inhibitory concentration, beta-lactamase genes and mortality for patients treated with piperacillin/tazobactam or meropenem from the MERINO study.
A Henderson,A Henderson,David L. Paterson,Mark D. Chatfield,Paul A. Tambyah,David C. Lye,David C. Lye,Partha Pratim De,Raymond T. P. Lin,Ka Lip Chew,Mo Yin,Tau Hong Lee,Tau Hong Lee,Tau Hong Lee,Mesut Yilmaz,R Cakmak,Thamer H. Alenazi,Yaseen M. Arabi,Marco Falcone,Matteo Bassetti,Elda Righi,Elda Righi,Rogers Ba,Souha S. Kanj,Hasan Bhally,Jon Iredell,Jon Iredell,Marc Mendelson,Tom H. Boyles,David Looke,David Looke,Naomi Runnegar,Naomi Runnegar,Spiros Miyakis,Spiros Miyakis,Spiros Miyakis,Genevieve Walls,M Ai Khamis,Ahmed Zikri,Amy Crowe,Paul R. Ingram,Paul R. Ingram,Nick Daneman,Paul M. Griffin,Paul M. Griffin,Paul M. Griffin,Eugene Athan,Leah W. Roberts,Scott A. Beatson,Anton Y. Peleg,Kyra Cottrell,Michelle J Bauer,E. Tan,K Chaw,Graeme R. Nimmo,Tiffany Harris-Brown,Patrick N A Harris,Patrick N A Harris,Merino Trial Investigators +58 more
TL;DR: Poor reliability in susceptibility testing performance for piperacillin/tazobactam and the high prevalence of OXA co-harboring ESBLs suggests meropenem remains the preferred choice for definitive treatment of ceftriaxone non-susceptible E. coli and Klebsiella.
Journal ArticleDOI
Comparable outcomes for β-lactam/β-lactamase inhibitor combinations and carbapenems in definitive treatment of bloodstream infections caused by cefotaxime-resistant Escherichia coli or Klebsiella pneumoniae
Patrick N A Harris,Mo Yin,Roland Jureen,Jonathan Chew,Jaminah Ali,Stuart Paynter,David L. Paterson,Paul A. Tambyah +7 more
TL;DR: BLBLIs appear to have a similar efficacy to carbapenems in the treatment of cefotaxime-resistant E. coli and K. pneumoniae bloodstream infections, and direct therapy with a BLBLI, when susceptibility is proven, may represent an appropriate carbAPenem-sparing option.
Journal ArticleDOI
Whole genome analysis of cephalosporin-resistant Escherichia coli from bloodstream infections in Australia, New Zealand and Singapore: high prevalence of CMY-2 producers and ST131 carrying blaCTX-M-15 and blaCTX-M-27
Patrick N A Harris,Nouri L. Ben Zakour,Leah W. Roberts,Alexander M. Wailan,Alexander M. Wailan,Hosam M. Zowawi,Hosam M. Zowawi,Paul A. Tambyah,David C. Lye,David C. Lye,David C. Lye,Roland Jureen,Tau H. Lee,Tau H. Lee,Mo Yin,Ezlyn Izharuddin,David Looke,David Looke,Naomi Runnegar,Naomi Runnegar,Benjamin A. Rogers,Hasan Bhally,Amy Crowe,Mark A. Schembri,Scott A. Beatson,David L. Paterson,David L. Paterson,Merino Trial Investigators +27 more
TL;DR: In a prospective collection of third-generation cephalosporin-resistant E. coli causing BSI, community-associated Clade C1/C2 ST131 predominate in association with blaCTX-M ESBLs, although a significant proportion of non-ST131 strains carried blaCMY-2.
Journal ArticleDOI
Atypical hand, foot, and mouth disease: eczema coxsackium can also occur in adults
TL;DR: A case of an adult patient with preexisting eczema who presented with hand, foot, and mouth disease and atypical lesions distributed in areas of eczematous skin, showing that this phenomenon is not limited to infants or young children.
Journal ArticleDOI
The contribution of hospital-acquired infections to the COVID-19 epidemic in England in the first half of 2020
Gwenan M. Knight,Thi Mui Pham,James A. Stimson,Sebastian Funk,Y Jafari,Diane Pople,Stephanie Evans,Mo Yin,Colin S Brown,Alex Bhattacharya,Russell Hope,Malcolm G Semple,Jonathan M. Read,Ben S. Cooper,Julie V. Robotham +14 more
TL;DR: In this paper , the authors used comprehensive national English datasets to determine the number of patients with identified hospital-acquired infections (with symptom onset > 7 days after admission and before discharge) in acute English hospitals up to August 2020.